#Press: The phase 3 trial with our house dust mite tablet in Chinese participants 12-65 years, has achieved its primary objective. With our partner GenSci, we’ll now work to file for regulatory approval in China: ir.alk.net #dklifescience #dkbiz #dkmedier #pharmanews
#Press: We've just announced an upgrade of our full-year financial outlook, reflecting a strong growth momentum in tablet sales across regions: rb.gy/ixhvzo. We will release our Q3 report on 17 November 2026. #dkbiz #dkmedier #pharmanews #dklifescience #dkpharma
#Press: We expanded our long-standing strategic tablet supply partnership w. @Catalent_. The agreement secures supply robustness & additional production capacity to sustain expected future demand for our tablets. me-l.co/cvrz1228 #dkmedier #dkbiz #pharmanews #dklifescience
Tina Olesen will join ALK as EVP of Corporate, Portfolio and Product Strategy. Our CEO says: “Tina’s nearly 30 years of commercial leadership experience, covering local and global perspectives, will be greatly appreciated.” shorturl.at/Bvynn #pharmanews #dkpharma #dkmedier
#PRESS: Today at 1.30 p.m. CEST, we’ll host a webcast conference call regarding ALK’s Q2 financial results for 2026. Here’s how to join the webcast: ir.alk.net #dkmedier #dkpharmanews #dkpharma #dkbiz #Q2results #interimreport #Q2report
Jacob Glenting appointed EVP, Global R&D, ALK. Our CEO says: “Jacob’s scientific background, long-standing ALK experience & ability to connect R&D and commercial strategy makes him uniquely qualified for the position” h1.nu/1wnJa #dkmedier #pharmanews #dkbiz #dkpharma
#PRESS: Q2 results published – incl. an outlook update. Our CEO says: “Our continued double-digit growth reflects the strength of our strategy and our firm commitment to helping people impacted by allergy worldwide.” shorturl.at/bB4hD #dkmedier #pharmanews #dkbiz #dkpharma
#PRESS: On Thursday 20 August we’ll announce our financial results for the 1st half of 2026. At 1:30 pm CEST, we’ll host a webcast conference call for investors & analysts. Here’s how to join ir.alk.net #dkmedier #pharmanews #dkpharma #dkbiz #interimreport #Q2results
#PRESS: ALK’s tree pollen & house dust mite tablets are now recommended by NICE in the UK for paediatric allergy treatment. With this, both tablets are now available to children and adults through the NHS: short.do/HRbQBD #pharmanews #dkbiz #dkmedier #dkpharma
#PRESS: We’re excited to announce that our nasal adrenaline spray, 2 mg, has been launched as the first needle-free emergency #anaphylaxis treatment for adults and children (> 30 kg) with severe allergies in Canada. shorturl.at/m5hFF #pharmanews #dkbiz #dkmedier #dkpharma
We find it important to support the open letter published by the European Life Sciences Coalition, urging #EU leaders to prioritise #lifesciences for #Europe & a stronger European life science ecosystem: shorturl.at/9DOeV @InvestEuropeEU @EU_Commission #EUpol #EUCommission
This year's #EAACI2026 is coming to an end - It's been four fantastic days in Istanbul! We're thankful for the great interest in our symposia. Should you have questions in this regard, please reach out to your local ALK office at ALK.net/select-country. #press #allergy #science
#PRESS: We’re excited to announce that the MHRA has approved our nasal adrenaline spray, 1 mg, as the first needle-free emergency #anaphylaxis treatment for young children (aged 4 and older, 15-30 kg) in the UK. rb.gy/frz2rd #pharmanews #dkbiz #dkmedier #dkpharma
It's day 4 at #EAACI2026! If you’re in Istanbul, Türkiye, for the conference, we hope you’ll come by and visit our booths D16 & D20 today, Monday 15 June. #EAACIcongress #allergy #HCPs #science @EAACI_HQ
Join the Flash Talk Session at #EAACI2026 today at 15:15-16:45 TRT on the humoral response to oral and skin sensitisation to peanut in Brown Norway rats. It will take place in room Athens at #EAACI2026. #allergy #EAACIcongress #HCPs #science #press @EAACI_HQ
We're excited to have Professor @RobertSGraham present a Flash Talk on the treatment of children with house dust mite allergy and with and without asthma in room Glasgow at #EAACI2026. Join the talk from 12:15-13:15 TRT #allergy #HCPs #science #press @EAACI_HQ
Join us for today's ALK symposium at #EAACI2026, 12:00-13:00. We're starting off with a session on the disease modifying & preventative benefits of AIT in #respiratoryallergy, chaired by Prof. Moisés Calderón Zapata. Find us in room Paris. #HCPs #press #science @EAACI_HQ
Join us at #EAACI2026: Apart from our symposium on #respiratory and #foodallergy, tomorrow includes an oral abstract session on the results from the real-world evidence RELY study on allergy immunotherapy. 13 June 13:15-14:45 TRT in room Gothenburg. #HCPs #press @EAACI_HQ
Three key poster sessions on different adrenaline administration forms for the treatment of #anaphylaxis will take place today, 12 June 12:00-13:00 TRT at #EAACI2026. Join the presentations by @DrDougMackMD and @PedAllergyDoc in the poster zone. #HCPs #press #science @EAACI_HQ
